Every drug approved in 2022: A year of fewer new products, but gene therapy firsts and new blockbusters
The year’s crop of US drug approvals won’t rival past vintages for quantity. But of the 45 drugs cleared for use by the FDA in 2022, a third are shaping up to be blockbusters, with high expectations for Lilly’s new diabetes drug, Bristol Myers Squibb’s TYK2 inhibitor and Gilead’s new HIV treatment.
The promise of gene therapy became a reality in 2022, with new funding for the FDA to work through its backlog of applications, and three new approvals for bluebird bio (for beta thalassemia and early cerebral adrenoleukodystrophy) and CSL (for hemophilia B). With those approvals came new breakthroughs in price: The $2 million-plus treatment costs are likely to further test the bounds of the commercial market.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.